Showing 31-40 of 44 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Designing a safe and effective strategy for T1D cell replacement therapy | The Regents of the University of California, San Francisco | Nur Shabrina Amirruddin | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Mechanisms of parathyroid protection of transplanted islets | The Regents of the University of California, San Francisco | Peng Xiao | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Northern California Breakthrough T1D Center of Excellence | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2024 to 30-September-2028 | $6,000,000.00 |
| Armored SC-beta | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-December-2023 to 30-November-2025 | $499,999.25 |
| Identifying regulators of primary human beta cell survival and proliferation | The Regents of the University of California, San Francisco | Rebecca Lee | Cures | 01-March-2024 to 28-February-2027 | $235,025.00 |
| Allogeneic hypoimmunogenic Pancreatic Islets for Treatment of Diabetes in the Intra-Muscular Site | The Regents of the University of California, San Francisco | Tobias Deuse | Cures | 01-August-2024 to 31-July-2026 | $799,998.40 |
| Investigating MAFA governed mechanisms underlying β-cell functional maturation and dysfunction using hPSC-derived β-cells | The Regents of the University of California, San Francisco | Veronica Cochrane | Cures | 01-July-2024 to 28-February-2027 | $231,222.03 |
| Prediction of Cancer Immunotherapy Precipitated Autoimmune Diabetes | The Regents of the University of California, San Francisco | Zoe Quandt | Cures | 01-March-2025 to 28-February-2030 | $1,000,000.00 |
| Development of Low Cost, High Precision Nano Pumps for Insulin Delivery | Torramics Inc. | Sergey Gimelshein | Improving Lives | 01-March-2023 to 31-August-2026 | $1,493,212.43 |
| Acetazolamide and Tubuloglomerular Feedback in Persons with Type 1 Diabetes: A Clinical Trial | University of California, San Diego | Charles Ginsberg | Improving Lives | 01-November-2022 to 31-October-2026 | $1,356,726.45 |